Journals / Turkish Journal of Gastroenterology / 2022 / Cilt: 33 - Sayı: 5

Bifidobacteria Was Decreased in Adult Patients With Irritable Bowel Syndrome Based on PCR and Bacterial Culture: A Systematic Review and Meta-Analysis

Pages
368–376
Publication Date
2022-11-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Future studies are warranted to further demonstrate the relationship between them.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The causes of irritable bowel syndrome remain unknown.
📊
Key Findings & Data:We performed a systematic meta-analysis of case–control studies from January 2000 to December 2020 to compare fecal microbes based on polymerase chain reaction and bacterial culture between adult irritable bowel syndrome patients and healthy controls.
💡
Conclusion & Impact:Future studies are warranted to further demonstrate the relationship between them.
🔬Design:Lab & Field Experiment
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

The causes of irritable bowel syndrome remain unknown. Studies and meta-analyses revealed that intestinal microbiota disturbance was one of the causes of irritable bowel syndrome, but the results remained controversial. Therefore, we performed a systematic review and meta-analysis to identify the association between them. We performed a systematic meta-analysis of case–control studies from January 2000 to December 2020 to compare fecal microbes based on polymerase chain reaction and bacterial culture between adult irritable bowel syndrome patients and healthy controls. The standardized mean difference value and a 95% CI were calculated. Two professional researchers used Newcastle–Ottawa Scale to reassess selected literature and extract highquality studies. Six studies were included in our analysis. When all eligible studies were pooled into the meta-analysis, compared with healthy controls, the standardized mean differences of Bifidobacteria (standardized mean difference = −1.01, 95% CI =: −2.01 to −0.01) in irritable bowel syndrome patients decreased significantly, whereas the standardized mean differences of Enterococcus, Enterobacter, Lactobacillus, Bacteroides, and Escherichia coli did not change significantly in irritable bowel syndrome patients. However, heterogeneity was significant to perform sensitivity analysis and stratified analysis in all these special intestinal microbes. In summary, this study indicated that only Bifidobacteria was decreased in irritable bowel syndrome patients compared with healthy controls using Newcastle–Ottawa Scale standards to extract high-quality literature. Future studies are warranted to further demonstrate the relationship between them.

🔖

Cite This Article

PENG, L., BU, Z., LIU, R., HUANG, B., YE, X. (2022). Bifidobacteria Was Decreased in Adult Patients With Irritable Bowel Syndrome Based on PCR and Bacterial Culture: A Systematic Review and Meta-Analysis. Turkish Journal of Gastroenterology, Cilt: 33 - Sayı: 5, 368–376. https://ajindex.com/articles/606214

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015
  2. 313(9):949-958. [CrossRef] 2. Gazouli M, Wouters MM, Kapur-Pojskić L, et al. Lessons learned- -resolving the enigma of genetic factors in IBS. Nat Rev Gastroenterol Hepatol. 2016
  3. 13(2):77-87. [CrossRef] 3. Martin CR, Osadchiy V, Kalani A, Mayer EA. The brain-gut-microbiome axis. Cell Mol Gastroenterol Hepatol. 2018
  4. 6(2):133-148. [CrossRef] 4. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet. 1996
  5. 347(8995):150-153. [CrossRef] 5. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014
  6. 11(8):497-505. [CrossRef] 6. Bhattarai Y, Muniz Pedrogo DA, Kashyap PC. Irritable bowel syndrome: a gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol. 2017
  7. 312(1):G52-G62. [CrossRef] 7. Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J Gastroenterol. 2016
  8. 22(7):2219-2241. [CrossRef] 8. Zhuang X, Xiong L, Li L, Li M, Chen M. Alterations of gut microbiota in patients with irritable bowel syndrome: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017
  9. 32(1):28-38. [CrossRef] 9. Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis. Dig Liver Dis. 2017
  10. 49(4):331-337. [CrossRef] 10. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011
  11. d5928. [CrossRef] 11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003
  12. 327(7414):557-560. [CrossRef] 12. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007
  13. 36(3):666-676. [CrossRef] 13. Francavilla R, Piccolo M, Francavilla A, et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Gastroenterol. 2019
  14. 53(3):e117-e125. [CrossRef] 14. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and